FTSE 100 movers: GlaxoSmithKline slumps on Avandia concerns
LONDON (ShareCast) - GlaxoSmithKline slumped to the bottom of the FTSE 100 movers on concern that problems with diabetes treatment Avandia might be serious.
ABN Amro chopped the drug major to 'hold' from 'buy' in reaction to reports Monday that its popular type 2 diabetes drug Avandia increases the risk of heart attack.
FULL STORY HERE
Zantac Lawsuit
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Please contact me if you would like a guest post considered for publication on my blog.
1 comment: